HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Naturals research

This article was originally published in The Rose Sheet

Executive Summary

Santerra Pharmaceuticals and Vedic Lifesciences have formed an alliance to further research in the natural cosmetics and health products segment in the North American market, firms state in an Oct. 30 release. The two contract research companies - based in Raleigh, N.C. and Mumbai, India, respectively - will work to provide critical skills, resources and turnkey developments in R&D while focusing on safety, laboratory and clinical studies. "Companies that market natural products seek to distinguish themselves from the competition through scientific excellence and by establishing the benefits of safety of their products in clinical trials," Santerra says. The alliance will provide "exceptional value" to natural products marketers, the firms claim, citing the "inherent cost benefits" of conducting studies in India...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel